Cargando…

Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population

BACKGROUND: The number of patients with diabetes mellitus (DM) presenting with coronary artery disease is increasing and accounts for more than 30% of patients undergoing percutaneous coronary interventions (PCI). The biodegradable polymer drug-eluting stents were developed to improve vascular heali...

Descripción completa

Detalles Bibliográficos
Autores principales: Gasior, Pawel, Gierlotka, Marek, Szczurek-Katanski, Krzysztof, Osuch, Marcin, Roleder, Magda, Hawranek, Michal, Wojakowski, Wojciech, Polonski, Lech
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078944/
https://www.ncbi.nlm.nih.gov/pubmed/31909473
http://dx.doi.org/10.5603/CJ.a2019.0111
_version_ 1783685133027508224
author Gasior, Pawel
Gierlotka, Marek
Szczurek-Katanski, Krzysztof
Osuch, Marcin
Roleder, Magda
Hawranek, Michal
Wojakowski, Wojciech
Polonski, Lech
author_facet Gasior, Pawel
Gierlotka, Marek
Szczurek-Katanski, Krzysztof
Osuch, Marcin
Roleder, Magda
Hawranek, Michal
Wojakowski, Wojciech
Polonski, Lech
author_sort Gasior, Pawel
collection PubMed
description BACKGROUND: The number of patients with diabetes mellitus (DM) presenting with coronary artery disease is increasing and accounts for more than 30% of patients undergoing percutaneous coronary interventions (PCI). The biodegradable polymer drug-eluting stents were developed to improve vascular healing. It was sought herein, to determine 1-year clinical follow-up in patients with DM treated with the thin strut biodegradable polymer-coated sirolimus-eluting stent (BP-SES) versus durable coating everolimus-eluting stent (DP-EES). METHODS: Patients were retrospectively analyzed with DM were treated with either a BP-SES (ALEX™, Balton, Poland, n = 670) or a DP-EES (XIENCE™, Abbott, USA, n = 884) with available 1 year clinical follow-up using propensity score matching. Outcomes included target vessel revascularization (TVR) as efficacy outcome and all-cause death, myocardial infarction, and definite/probable stent thrombosis as safety outcomes. RESULTS: After propensity score matching 527 patients treated with BP-SES and 527 patients treated with DP-EES were selected. Procedural and clinical characteristics were similar between both groups. In-hospital mortality was 3.23% in BP-SES vs. 2.09% in DP-EES group (p = 0.25). One-year follow-up demonstrated comparable efficacy outcome TVR (BP-SES 6.64% vs. DP-EES 5.88%; p = 0.611), as well as similar safety outcomes of all-cause death (BP-SES 10.06% vs. DP-EES 7.59%; p = 0.158), myocardial infarction (BP-SES 7.959% vs. DP-EES 6.83%; p = 0.813), and definite/probable stent thrombosis (BP-SES 1.14% vs. DP-EES 0.76%; p = 0.525). CONCLUSIONS: The thin-strut biodegradable polymer coated, sirolimus-eluting stent demonstrated comparable clinical outcomes at 1-year after implantation to DP-EES. These data support the relative safety and efficacy of BP-SES in diabetic patients undergoing PCI.
format Online
Article
Text
id pubmed-8078944
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Via Medica
record_format MEDLINE/PubMed
spelling pubmed-80789442021-05-10 Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population Gasior, Pawel Gierlotka, Marek Szczurek-Katanski, Krzysztof Osuch, Marcin Roleder, Magda Hawranek, Michal Wojakowski, Wojciech Polonski, Lech Cardiol J Interventional Cardiology BACKGROUND: The number of patients with diabetes mellitus (DM) presenting with coronary artery disease is increasing and accounts for more than 30% of patients undergoing percutaneous coronary interventions (PCI). The biodegradable polymer drug-eluting stents were developed to improve vascular healing. It was sought herein, to determine 1-year clinical follow-up in patients with DM treated with the thin strut biodegradable polymer-coated sirolimus-eluting stent (BP-SES) versus durable coating everolimus-eluting stent (DP-EES). METHODS: Patients were retrospectively analyzed with DM were treated with either a BP-SES (ALEX™, Balton, Poland, n = 670) or a DP-EES (XIENCE™, Abbott, USA, n = 884) with available 1 year clinical follow-up using propensity score matching. Outcomes included target vessel revascularization (TVR) as efficacy outcome and all-cause death, myocardial infarction, and definite/probable stent thrombosis as safety outcomes. RESULTS: After propensity score matching 527 patients treated with BP-SES and 527 patients treated with DP-EES were selected. Procedural and clinical characteristics were similar between both groups. In-hospital mortality was 3.23% in BP-SES vs. 2.09% in DP-EES group (p = 0.25). One-year follow-up demonstrated comparable efficacy outcome TVR (BP-SES 6.64% vs. DP-EES 5.88%; p = 0.611), as well as similar safety outcomes of all-cause death (BP-SES 10.06% vs. DP-EES 7.59%; p = 0.158), myocardial infarction (BP-SES 7.959% vs. DP-EES 6.83%; p = 0.813), and definite/probable stent thrombosis (BP-SES 1.14% vs. DP-EES 0.76%; p = 0.525). CONCLUSIONS: The thin-strut biodegradable polymer coated, sirolimus-eluting stent demonstrated comparable clinical outcomes at 1-year after implantation to DP-EES. These data support the relative safety and efficacy of BP-SES in diabetic patients undergoing PCI. Via Medica 2021-04-13 /pmc/articles/PMC8078944/ /pubmed/31909473 http://dx.doi.org/10.5603/CJ.a2019.0111 Text en Copyright © 2021 Via Medica https://creativecommons.org/licenses/by-nc-nd/4.0/This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
spellingShingle Interventional Cardiology
Gasior, Pawel
Gierlotka, Marek
Szczurek-Katanski, Krzysztof
Osuch, Marcin
Roleder, Magda
Hawranek, Michal
Wojakowski, Wojciech
Polonski, Lech
Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population
title Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population
title_full Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population
title_fullStr Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population
title_full_unstemmed Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population
title_short Biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population
title_sort biodegradable polymer-coated thin strut sirolimus-eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population
topic Interventional Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078944/
https://www.ncbi.nlm.nih.gov/pubmed/31909473
http://dx.doi.org/10.5603/CJ.a2019.0111
work_keys_str_mv AT gasiorpawel biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation
AT gierlotkamarek biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation
AT szczurekkatanskikrzysztof biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation
AT osuchmarcin biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation
AT roledermagda biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation
AT hawranekmichal biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation
AT wojakowskiwojciech biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation
AT polonskilech biodegradablepolymercoatedthinstrutsirolimuselutingstentversusdurablepolymercoatedeverolimuselutingstentinthediabeticpopulation